System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Franco Scaldaferri is an expert in Gastroenterology at Agostino Gemelli University Polyclinic (Italy). As of October 2026, ScienceLeadR ranks Franco Scaldaferri in the top 1% of experts worldwide for Inflammatory Bowel Diseases, Gastroenteritis and Colitis. Franco Scaldaferri has authored 587 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 14 of them ongoing. SLR score: 2,261 (community average: 125). How the SLR is computed.

LeadR Profile

Franco Scaldaferri Agostino Gemelli University Polyclinic Italy
2 261 ScienceLeadR Reputation 2261

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Biochemistry - Nutrition - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Catholic University of the Sacred Heart

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 587

Citations

Citations: 12 612 1st author: 57 Last author: 136 Unique author: 0

Main journals

Dig Liver Dis 128
J Crohns Colitis 93
Gastroenterology 33
Eur Rev Med Pharmacol Sci 28
Inflamm Bowel Dis 18

Best Journals

Lancet Gastroenterol Hepatol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Beyond Crohn's disease: ileal Kaposi sarcoma in a transplant recipient presenting with subocclusive symptoms. A concomitant diagnosis of Crohn's disease and ileal Kaposi sarcoma.
PMID 42839839 — ileal diseases, sarcoma, kaposi, crohn disease, sarcoma, signs and symptoms, diagnosis, transplants, therapeutics, immunosuppression therapy		Minerva Gastroenterol (Torino)20260
Generational differences in illness perception among adults with inflammatory bowel disease: a multicenter cross-sectional study.
PMID 42765299 — liver diseases, cross-sectional studies, health behavior, perception, inflammatory bowel diseases, therapeutics, gastrointestinal diseases		Eur J Gastroenterol Hepatol20260
Preoperative myopenia is associated with postoperative complications and endoscopic recurrence after ileocolic resection in Crohn's disease.
PMID 42718949 — muscles, crohn disease, postoperative complications		Ther Adv Gastroenterol20260
Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
PMID 42720163 — safety, crohn disease, inflammatory bowel diseases, pharmacology, therapeutics, prospective studies		Aliment Pharmacol Ther20261
IBD Nurse-Led Clinical Pathways to Optimize Patient Safety in Advanced Therapies: A Narrative Review.
PMID 42704580 — nurses, patient safety, safety, gastroenterology, nursing, therapeutics, education		Dig Dis Sci20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 9

By phase:

N/A 11
Phase 2 5
Phase 3 4

By status:

Recruiting 12
Completed 4
Not yet recruiting 2
Active not recruiting 1
Unknown 1

By type:

Interventional 13
Observational 7

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 0
multicentric5to9 1
multicentricup10 12

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

14 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
LY4268989 (MORF 057) Co Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis A Phase 2 Study
2025-522338-30-00 — colitis, colitis, ulcerative		Phase 2Recruiting2026
A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis
2024-518998-33-00 — colitis, therapeutics, colitis, ulcerative		Phase 3Active not recruiting2025
A Master Protocol (IIBD) A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn s Disease
NCT07483073 — colitis, crohn disease, pharmaceutical preparations, therapeutics, colitis, ulcerative		Phase 2Recruiting2026
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn s Disease
NCT07483099 — crohn disease		Phase 2Recruiting2026
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN s Disease
NCT07363044 — blood, crohn disease, probability, epigenome, therapeutics, software, biological therapy		N/ARecruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS